Hippo ERcast November 2021

Is it worth it to check a serum magnesium?

Hypokalemia often travels with magnesium deficiency, and low magnesium makes potassium repletion fail. The catch is that serum magnesium is a poor proxy for total-body or intracellular magnesium, so emergency decisions about checking or empirically replacing magnesium are less straightforward than dogma suggests. Magnesium and Potassium Physiology Refractory hypokalemia mechanism: Magnesium deficiency impairs Na-K-ATPase activity and promotes renal potassium wasting in the distal nephron, making hypokalemia persist despite potassium replacement alone. Frequent clinical overlap: More than half of clinically significant hypokalemia may coexist with magnesium deficiency, which is why low potassium and low magnesium are so often linked in practice. Potassium retention role: Magnesium supports both intracellular potassium storage and renal conservation, so deficiency creates a true potassium-wasting state rather than just an abnormal lab pairing. Why magnesium helps: Co-administering magnesium can be essential when potassium will not correct, especially when the picture suggests ongoing urinary losses. We get into the bedside reasoning in the episode. Should You Check a Magnesium Level Serum level limitation: Only about 1% to 2% of body magnesium is extracellular, so a standard serum magnesium level samples a tiny compartment rather than meaningful total-body stores. Wrong analyte problem: Routine magnesium testing reports total magnesium, not readily available ionized magnesium, even though the ionized fraction is the biologically active form. Poor tissue correlation: Serum magnesium correlates poorly with intracellular and skeletal muscle magnesium, and deficiency can exist even when the measured serum value is normal or high. Laboratory reliability concerns: A 2017 critical care study found that more than 80% of low total magnesium results were erroneous, adding another reason not to over-trust the number. Empiric replacement judgment: Practice varies: some clinicians give magnesium whenever repleting significant hypokalemia, while others reserve empiric treatment for higher-risk patients like diuretic users, drinkers, and diabetics. We lay out that split in the podcast.

EEM Rewind: Cam Berg's C Diff Pathway

Clostridioides difficile is a clinical syndrome, not just a positive stool test. Chronic watery diarrhea, recent antibiotics or hospitalization, immunosuppression, and even proton pump inhibitor exposure all change pretest probability, while PCR-toxin discordance often identifies colonization rather than active infection. C difficile diagnosis and testing Syndrome over positive test: C difficile should be suspected in prolonged diarrhea with compatible risk factors, not in every loose stool; hyperacute illness is less typical, and symptoms often persist for weeks before testing is worth pursuing. Proton pump inhibitor risk: PPI exposure is a meaningful C difficile risk factor, and that elevated risk can persist for up to 1 year after the drug is stopped. Two step stool testing: PCR is highly sensitive but poor at separating infection from colonization, so a follow-up toxin EIA is what distinguishes active disease from an asymptomatic carrier state. Carrier versus active disease: PCR positive and EIA negative patients are usually colonized rather than infected; isolate them, but antibiotics are generally unnecessary. We walk through the practical interpretation in the chapter. Retesting after recent infection: PCR can remain positive long after appropriate treatment, so repeat testing soon after a known infection may mislead more than it helps. Immunosuppression as exception: Immunosuppressed patients are the main group where a PCR positive, EIA negative result may still represent true disease, so clinical judgment may favor treatment despite discordant testing. C difficile treatment decisions Oral vancomycin first line: Oral vancomycin is the preferred initial therapy because metronidazole resistance has eroded confidence in older regimens. No role for IV vancomycin: IV vancomycin does not treat luminal C difficile because the drug needs to reach the gut directly, making the oral route the clinically relevant one. Empiric therapy restraint: Outside of a toxic hospitalized patient, empiric treatment is usually the wrong move; if no stool sample is available, it is reasonable to wait for a specimen rather than guess. Recurrent diarrhea after treatment: Recent treated C difficile complicates repeat testing because PCR may stay positive; there is a practical approach to suspected recurrence that relies more on clinical judgment than another swab. We get into that nuance in the episode. Enteric panel overuse: Reflex enteric pathogen panels are often low value in otherwise well patients with diarrhea, expensive, and prone to finding organisms that do not change management.

Lit Matters #1: WASP - Wheeze and Steroids in Preschoolers

Preschool viral wheeze is a heterogeneous syndrome, and it does not behave like established asthma. In children with URI-associated wheezing, oral prednisolone may improve early symptoms and possibly reduce admission, but most are markedly better by 24 hours either way. Preschool Wheeze and Steroids Heterogeneous preschool wheeze: Viral URI-associated wheeze in preschoolers is not synonymous with asthma; in this trial, about 90% had prior wheeze but only roughly one-third carried an asthma diagnosis. Primary outcome signal: The main endpoint was change in Preschool Respiratory Assessment Measure at 24 hours, and prednisolone did not improve that primary outcome over placebo. Early symptom improvement: Prednisolone showed its clearest benefit at 4 hours, with lower absolute PRAM scores and less need for escalation, a timing nuance we get into in the episode. Hospitalization trend: Admission rates trended lower with steroids, 23.5% versus 31.4%, suggesting a possible operational benefit even though statistical certainty was limited. Natural history at 24 hours: The key bedside reality is that most preschoolers with viral wheeze are much better by 24 hours with or without steroids, which should temper repeat dosing. Practical steroid takeaway: If steroids are used, the signal favors giving them early rather than layering on extra doses later; we walk through the restraint piece in the chapter.

Toxic Shock Syndrome

Toxic shock syndrome is a toxin-mediated shock state caused most often by Staphylococcus aureus or Streptococcus pyogenes, with mortality that can reach 30-80%. Early diagnosis is clinical, not criteria-driven: hypotension plus organ dysfunction should prompt a search for a hidden source infection and immediate treatment. Recognizing Toxic Shock Syndrome Superantigen pathophysiology: TSS is driven by bacterial superantigens that bypass normal immune checkpoints, triggering massive cytokine release and rapid end-organ injury rather than a simple localized infection. Usual causative organisms: Staphylococcus aureus and Streptococcus pyogenes cause most cases, with staph now often tied to postoperative, postpartum, burn, or focal infections rather than tampon use alone. Classic but unreliable triad: Fever, hypotension, and a blanching diffuse red rash are the classic clues, but many patients present first with vomiting, diarrhea, myalgias, weakness, and chills instead. Criteria versus bedside diagnosis: CDC criteria differ for staph and strep TSS, but both hinge on hypotension and multisystem organ failure; the practical gaps between criteria and real-time diagnosis are worth hearing in the episode. Delayed desquamation finding: Desquamation of the palms and soles may not appear until 1-3 weeks into illness, making strict case definitions poorly suited to early emergency department recognition. Important clinical mimics: Adrenal insufficiency, septic shock, meningococcemia, and myocarditis can resemble TSS, especially when the presentation looks like a nonspecific viral illness tipping into shock. Source Search and Early Treatment Hidden infection source: Once TSS is suspected, aggressively look for the source because toxin-producing infections can be deceptively quiet, with little redness, purulence, or localizing pain. Stealth soft tissue disease: Streptococcal TSS may accompany necrotizing fasciitis, myositis, cellulitis, or penetrating injury, especially when systemic toxicity seems out of proportion to the exam. Culture limitations: Blood cultures are frequently negative in staphylococcal TSS and miss a substantial share of streptococcal cases, so a negative culture should not reassure you early. High-risk ED scenarios: Think TSS in a young patient with viral-like symptoms and septic shock, or in any patient whose vitals and overall toxicity feel far worse than the chief complaint. Immediate management priority: Treatment starts with source control and early therapy rather than waiting for formal criteria to be met. We get into the bedside approach in the chapter.

Lit Matters #2: BaSICS Trial - Type of Fluid

In critically ill adults needing fluid challenges, Plasma-Lyte 148 did not beat 0.9% saline for 90-day mortality in the BaSICS trial. This large ICU randomized trial also found no consistent signal across secondary outcomes or most subgroups, with a cautionary note around traumatic brain injury. BaSICS Fluid Type Trial Primary mortality outcome: Ninety-day mortality was essentially unchanged with balanced crystalloid versus normal saline, arguing against a broad survival advantage from choosing Plasma-Lyte 148 in undifferentiated critical illness. Large pragmatic ICU sample: More than 10,000 patients across 75 Brazilian ICUs make this one of the biggest fluid-type trials in critical care, and the enrollment details matter when judging how far to generalize the result. Pre-ICU fluid exposure: Most patients had already received crystalloids before ICU enrollment, and nearly half of those got more than 1 liter, a design feature that may dilute any later between-group fluid effect. Illness severity snapshot: This was a genuinely sick cohort: about 61% had hypotension or vasopressor use and 44% were mechanically ventilated, which helps frame why a mortality signal would have mattered if present. Subgroup signal in TBI: Traumatic brain injury stood out as a possible exception, with worse outcomes seen in the balanced-fluid group, though the authors note important measurement caveats. We get into why that signal is hard to ignore in the episode. No subgroup rescue: Secondary and subgroup analyses did not uncover a convincing population that clearly benefited from balanced solution, reinforcing saline as a reasonable default when the indication is simply initial ICU fluid challenge.

Post-Contrast AKI Controversy

Modern evidence suggests IV iodinated contrast is not a proven cause of acute kidney injury in most ED patients. Post-contrast AKI is usually a serum creatinine rise temporally linked to contrast, but comorbidity, illness severity, and selection bias explain much of the old dogma around contrast nephropathy. Post-Contrast AKI Evidence Update Terminology shift to PC-AKI: Post-contrast acute kidney injury has replaced contrast-induced nephropathy, reflecting that a creatinine rise after contrast is an association in time, not proof the contrast caused the kidney injury. KDIGO creatinine definition: KDIGO defines PC-AKI by a serum creatinine rise within 48 hours after contrast exposure, but that threshold captures many patients whose AKI may be driven by sepsis, hypoperfusion, or nephrotoxins instead. Bias in older literature: Much of the classic CIN literature was observational, with strong selection and confounding bias because sicker patients or those with worse renal function were often denied contrast in the first place. Clinically meaningful outcomes: The better question is not a transient creatinine bump but dialysis, persistent renal dysfunction, or death, and newer studies across specialties have not shown a signal for harm there. We get into why that outcome framing matters in the episode. Modern contrast formulations: Today's low-osmolar agents are less concentrated than older high-osmolar contrast, making historical assumptions about tubular toxicity and renal vasoconstriction harder to apply to current CT practice. Multi-specialty evidence base: Large cohorts, meta-analyses, and the AMACING trial all point the same direction: for most patients getting IV contrast CT, contrast itself does not appear to increase AKI, dialysis, or mortality. Who Still Warrants Caution Excluded high-risk groups: Caution remains reasonable in renal transplant recipients, patients with serum creatinine at or above 4.0 mg/dL, and those with eGFR below 30 mL/min/1.73 m2 because these groups were commonly excluded from modern studies. Pre-existing renal insufficiency: The American College of Radiology consensus identifies severe baseline renal dysfunction as the most credible risk factor, while many other proposed risks have not been rigorously confirmed. Hydration dogma questioned: Routine prophylactic IV hydration before contrast has weaker support than many clinicians assume, and one major randomized trial found no preventive benefit in the studied population. We walk through the practical implications in the chapter. Persistent practice variation: The controversy persists because nephrology, radiology, internal medicine, and emergency medicine have emphasized different datasets, and changing long-held renal safety habits is harder than citing one paper.

Lit Matters #3: BaSICS Trial - Rate of Fluid

In critically ill patients receiving a fluid challenge, bolus speed alone did not change 90-day mortality in the BaSICS trial. This large ICU randomized trial speaks directly to emergency and critical care questions about IV fluid rate, resuscitation strategy, and whether slower infusion improves outcomes. BaSICS Fluid Rate Trial Mortality outcome signal: A slower fluid bolus rate did not improve 90-day mortality compared with a faster rate, reinforcing that infusion speed by itself is not a mortality lever in broad critical illness. Headline infusion rates: The trial compared 333 mL/hr versus 999 mL/hr, giving a concrete bedside definition of what the authors meant by slower and faster fluid administration. Large pragmatic ICU sample: More than 10,000 patients across 75 ICUs were randomized, which gives the negative primary result unusual weight for clinicians deciding how much to trust it. Early organ support signal: By day 3, the slower-rate group showed slightly better SOFA-related hemodynamic and respiratory findings, including less vasopressor use and less severe oxygenation failure. Transient secondary differences: Those early physiologic advantages were not sustained by day 7, a useful reminder that short-term organ support signals do not necessarily translate into durable patient-centered benefit. We get into why that matters in the episode.

Legally Defensible Charting

Legally defensible charting is less about volume and more about showing your clinical reasoning. In emergency medicine documentation, the safest note explains why a high-risk diagnosis was considered but not believed, what you think is most likely instead, and what uncertainty was discussed with the patient. Defensible Emergency Department Charting Core purpose of charting: A strong ED note has three jobs: communicate with other clinicians, support billing, and show whether the standard of care was met when decisions are later scrutinized. Problem-focused clinical record: Defensibility starts by documenting what you actually did, with complaint-specific details like an ECG for chest pain or an abdominal exam for a child with abdominal pain. High-risk diagnosis rationale: The key legal protection is a customized MDM that states the dangerous diagnosis you considered and why the presentation made it less likely, not a generic denial. Most likely diagnosis framing: Notes are stronger when they name what you do think is going on, along with the uncertainty discussed, additional workup offered, and return precautions given. Template customization pitfalls: Dot phrases help only when they are individualized; auto-populated laundry-list differentials can backfire by implying you never truly considered the diagnosis that was missed. We get into a practical wording approach in the episode. AMA refusal documentation value: When patients decline recommended testing or treatment, documenting the discussion, the decision against advice, and the invitation to return can be as protective as an AMA form. Scribes, Macros, and Narrative Detail Scribe role boundaries: Scribes can reduce screen time and improve workflow, but the final medical decision-making should remain yours and should be completed with case-specific language. Macro design principles: The safest macro is a generic scaffold you finish yourself, often with only a few added words tied directly to the chief complaint and bedside findings. Chief complaint specificity: If you use templates, add at least one concrete detail showing you evaluated this patient rather than merely checking boxes, especially in the history and exam. Color within boundaries: Behavioral context matters when it affects care delivery; quoting hostile or aggressive statements can clarify the environment without adding editorial or insulting language. Care environment standard: Standard of care is judged in context, so documenting limited resources or a hostile encounter can explain why care differed from an ideal workflow. That distinction is worth hearing in the chapter.